MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: Together, these findings indicate that celecoxib may serve as a COX2-independent lead compound to simultaneously target the mTOR and β-catenin pathways, key players in the resistance of CML stem cells to TKIs.